<DOC>
	<DOCNO>NCT02093273</DOCNO>
	<brief_summary>The objective study compare antibody response 30 day two dos OPV</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Profile Trivalent OPV ( tOPV Bio Farma )</brief_title>
	<detailed_description>The trial design phase II , randomize , double blind , prospective intervention study . The subject study 240 healthy , full term , newborn infant .</detailed_description>
	<criteria>Healthy , full term , newborns infant newborn reside within relatively short easily accessible distance A ( &lt; 30km ) study clinic ( ) plan travel away entire study period Infant bear 37 week pregnancy Infant weigh 2.5kg birth ( birth weight &gt; = 2.5kg ) Healthy newborn , history asphyxia meconium aspiration Father , mother legally acceptable representative properly inform study sign informed consent form . Parents commit comply indication investigator schedule trial Mother least elementary school graduate Child concomitantly enrol schedule enrol another trial Known history congenital acquire immunodeficiency ( include HIV infection ) Evolving moderate severe illness , especially infectious disease fever ( axillary temperature &gt; =37.5oC Newborns require hospitalization birth Infant immunize nonscheduled OPV IPV trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>tOPV</keyword>
	<keyword>Antibody response</keyword>
	<keyword>Safety</keyword>
</DOC>